• A
  • A
  • A

Dennis K. Galanakis, MD, Professor

Dennis K. Galanakis, MD
Professor of Pathology and Medicine

Director of Blood Bank
University Hospital, Level 5
Stony Brook Medicine
Stony Brook, NY 11794-7530

Tel: (631) 444-2625  
Fax: (631) 444-3137 
Email:  Dennis.Galanakis@stonybrookmedicine.edu
 
Clinical Practice
Dr. Galanakis is Board Certified in Clinical Pathology (1978), with subspecialty expertise in Transfusion Medicine, Apheresis, and Coagulation. He has extensive experience as Director of a Fellowship training program in Transfusion Medicine since 1991. He regularly receives consultations from local and distant metropolitan area physicians for apheresis of patients with a variety of diseases. He has published many studies on fibrinogen and is particularly well known for his expertise in familial fibrinogen anomalies. Dr. Galanakis has pioneered a procedure that stops excessive bleeding from surgery by use of the patient’s own platelet rich plasma. Adaptations of this procedure have been successfully used to minimize transfusion in open heart surgery and in burn patients, and to treat seromas.

Research Summary
Dr. Galanakis is internationally known for his published studies of normal fibrinogen variants and of inherited fibrinogen disorders. He regularly receives requests to evaluate such families from physicians in different states and countries, and such evaluations at times result in benefit to these families. In particular, loss of pregnancy has been avoided in many instances with such disorders, as a result of recommendations emanating from his tests and evaluations of such families. He has also published basic studies on the structure/function relationships of fibrinogen and on interactions of fibrinogen with other proteins and platelets.


Education
Institution and Location Degree Year(s) Field of Study
Wagner College, SI, NY B.S. 1958 Biology
Univ. of Saskatchewan, Canada M.D. 1962 Medicine

Positions and Employment

1962-63
Rotating Intern: Meamonides Hospital, Brooklyn, NY
1963-65
Resident in Internal Medicine, Manhattan VA Hospital
1965-67 Fellow in Clinical Hematology, NY Medical College
1968-70 Research Fellow in Coagulation (Medicine)
1975-77 Resident in Clinical Pathology, Downstate Medical Center, Brooklyn, NY


Honors (selected)

1955-62    
Marshall, H. and Nellie Alworth Scholarship
1956     
Best Freshman Scholarship, Wagner College
1988-92
Member of Editorial Board, Thrombosis Research journal
1994-07
Member of the Council of Human Blood and Transfusion Services of NY State Department of Health, Chair of the Council, 1998-2007
2000 Fellow of American Heart Association
2007
Distinguished Service Award, NYS Department of Health
2007
Chancelor’s Award for Excellence in Faculty Service
2012Excellence in Clinical Service Award, Department of Pathology

Peer Reviewed Publications
Galanakis, D.K. and Mosesson, M.W.  Evaluation of in vivo proteolysis (fibrinogenolysis) in prolonging the thrombin time of human umbilical cord fibrinogen.  Blood  1976; 48:109.

Galanakis, D.K., Mosesson, M.W. and Stathakis, N.E.  Human fibrinogen heterogeneities. Distribution and charge characteristics of aa chains and aa remnants in plasma fibrinogen molecules. J Lab Clin Med  1978; 92:376.

Galanakis, D.K., Laurent, P., Janoff, A., Chung, S.I.  Cigarette smoke contains anticoagulants against fibrin aggregation and factor xiiia in plasma.   Science  1982; 217: 642-645.

Galanakis, D.K. and Mosesson, M.W.  The Aa chain composition of plasma fibrinogen catabolites. Thromb Res 1983; 15: 287.

Galanakis, D.K. and Mosesson, M.W. Human fibrinogen heterogeneities: determination of the major Aa chain derivatives in blood.   Thromb Res  1983; 31: 403-413.

Galanakis, Dennis K., Lane, Bernard P., & Simon, Sanford R. Albumin Modulates lateral assembly of fibrin polymers: evidence of enhanced fine fibril formation and of unique synergism with fibrinogen.  Biochemistry 1987; 26: 2389-2400.

Galanakis, D.K., A. Henschen, E.I.Peerschke, and M. Kehl.  Fibrinogen stony brook, a heterozygous aa 16arg-cys dysfibrinogenemia. Evaluation of Diminished Platelet Aggregation Support and of Enhanced Inhibition of Fibrin Assembly. J Clin Invest 1989; 84: 295-304.

Galanakis, D.K., Spitzer S., Scharrer I. An unique dysfibrinogenemic family: Aa 16Arg- Cys accompanied by lack of normal Aa chains in fibrinogen from two of the four probands. Blood Coag & Fibrinol 1993; 4 : 67-71.

Galanakis, D.K. and B. Ghebrehiwet. A unique property of a plasma proteoglycan, the C1q inhibitor: anticoagulant state resulting from its binding to fibrinogen. J Clin Invest 1994; 93: 303-310.

Galanakis, D.K. Studies of plasma cryoprecipitation: major increase in fibrinogen yield by albumin enrichrment of plasma.  Thromb Res  1995; 78: 303-313.

Galanakis, D.K, Nuovo G, Spitzer S, Kaplan C. Co-presence of fibrinogen mRNA and antigen in human trophoblasts in situ. Posible significance. Thromb Res  1996; 81: 263-269.

Grieninger, G. Lu, XH. Cao, Y., Fu YP., Kudryk BJ. Galanakis DK. Hertzberg KM. Fib(420), the novel fibrinogen subclass - newborn levels are higher than adult. Blood. 1997; 90 :2609-2614. 

Galanakis, DK, Neerman-Arbez M, Scheiner T, Henschen A, Hubbs D, Nagaswami C, Weisel J. Homophenotypic Aa R16H Fibrinogen (Kingsport): Uniquely Altered Polymerization Associated with Slower Fibrinopeptide A than Fibrinopeptide B Release. Blood Coag & Fibrinol, 2007; 18:08: 731-737.

Galanakis DK, Neerman-Arbez M, Kudryk B, Henschen A. Decreased plasmin resistance by clots of a homophenotypic Aa R16H fibrinogen (Kingsport, slower fibrinopeptide A than fibrinopeptide B release). Blood Coag Fibrinol, 2010; 21:135-9.

Schachtrup C, Ryu JK, Helmrick MJ, Vagena E, Galanakis DK, Degen JL, Margolis RU, Akassoglou K. Fibrinogen triggers astrocyte scar formation by promoting the availability of active TGF-beta after vascular damage. J Neurosci, 2010 ;30 :5843-54.

Koo J, Rafailovich MH, Medved L, Tsurupa G, Kudryk BJ, Galanakis DK. Evaluation of Fibrinogen Self-assembly: Role of its αC Region. J Thromb Haemost, 2010; 8: 2727–35.

Koo J, Galanakis D, Yin L, Ramek A, Xiaolan B, Simon M, Rafailovich M. Control of Anti-Thrombogenic Properties: Surface-Induced Self-Assembly of Fibrinogen Fibers. J Biomacromol, 2012;13:1259-68.

Ghebrehiwet B, Ji Y, Valentino A, Pednekar L, Ramadass M, Habiel D, Kew RR, Hosszu KH, Galanakis DK, Kishore U, Peerschke EI. Soluble gC1qR is an Autocrine Signal that Induces B1R Expression on Endothelial Cells. J Immunol 2014; 192: 377-384.

Dennis K Galanakis, Marguerite Neerman-Arbez, Steven Brennan, Miriam Rafailovich, Luke Hyder, Anthi Travlou, Emmanuel Papadakis, Marilyn J Manco-Johnson, Agnes Hanschen, Inge Scharrer. Thromboelastographic Phenotypes of Fibrinogen and its Variants: Clinical and Non-clinical Implications. Thromb Res 2014; 133: 1115-1123.

Peer Reviewed by Editor

Galanakis, D.K., Henschen, A., Keeling, M., Kehl, M., Dismore, R. and Peerschke, E.I.  Fibrinogen Louisville: An Aa 16Arg-His Defect which Forms no hybrids in Heterozygous Individuals and Inhibits Aggregation of Normal Fibrin Monomers. Ann NY Acad Sci  408, 644-648, 1983.

Galanakis, D.K., Martinez, J., McDevitt, C. and Miller, F.  Human Fetal Fibrinogen: Its Characteristics of Delayed Fibrin Formation, High Sialic Acid AP Peptide Content are more in Pre-term than in Term Samples.  Ann NY Acad Sci  408, 640-643, 1983.

Galanakis, Dennis K. & Weigand Kurt. Albumin Inhibition of Lateral Fibrin Assembly: Certain Characteristics and Possible Physiologic Significance. Fibrinogen and its Derivatives-Biochemistry, Physiology and Pathophysiology.  Muller-Berghaus et al., Eds.  Excerpta Medica, Amsterdam, 1987, pp 71-79.

Galanakis, D.K. and Henschen, A. Aspects of Evaluation of Fibrinogen Stony Brook: A Defect Resulting in Failure to Release Peptide A.   Proceedings of Symposium on Fibrinogen Structure and Function, W. De Gruyter and Co. ( A.Henschen et al., Eds.) 1985, pp 207-212.

Galanakis, D.K. Differences and Similarities Between Human Adult and Fetal Fibrinogen D1Fragments.  Proceedings of Symposium on Fibrinogen Structure and Function, W. De Gruyter and Co. (A. Henschen et al. Eds.) 1985, pp 147-154.

Peerschke, E.I. and Galanakis, D.K. Binding of Fibrinogen to ADP-treated Platelets: Importance of the A alpha Chain.  Proceedings of Symposium on Fibrinogen Structure and Function, W. De Gruyter and Co. (A. Henschen et al., Eds.) 1985, pp 369-378.

Galanakis D.K. Comparison of Impedance Measurements of Lepto- and Pachy-fibril Rich Fibrin Gels.  In: Fibrinogen 2. Biochemistry, Physiology, Clinical Relevance. G.D.O. lowe, J.T. Douglas, C.D.Forbes, and A. Henschen, Editors. Excerpta Medica, Amsterdam-New York-Oxford, 1987, p 19-23.

Galanakis D.K., A.Henschen, E.Peerschke, M. Kehl.  Fibrinogen Stony Brook, an Heterozygous A a16Arg®  Cys Dysfibrinogenemia: Evidence of Heterodimers Educed from Functional Analyses. In: Fibrinogen 2. Biochemistry, Physiology, Clinical Relevance. Excerpta Medica, 1988, p. 251-258.

Galanakis D.K, W. Schuback, A. Henschen, and H. Al Mondhiri. Fibrinogens Hershey II and Leogan, Heterozygously Expressed Aa16Arg® Cys Substitutions Identified by DNA Sequence and by by Amino Acid Sequence Analyses. Fibrinogen 2. Biochemistry, Physiology, Clinical Relevance.  (1). Excerpta Medica, 1989, pp 173-178.

Ghebrehiwet B, Galanakis D. Preparation and Properties of the C1q Inhibitor (Chondroitin- 4 Sulfate Proteoglycan): Structure and Function. In: Structure-Fucntion Relationship of C1q and Collectins, C1-estera-ses: C1r, C1s, and the C1 Inhibitor. Behring Inst. Mitteilungen 93: 213-223, 1993.

Chung SI, Galanakis DK, Folk JE. Factors that Influence Factor XIIIa Activity in vivo. Effects of Thiols and Albumin. in: Factor XIII 2nd International Conference Proceedings. J. McDonagh, P. Seitz, R. Egbring, eds. Schattauer, NY 1993, p 31-39.

Galanakis DK, Henschen A, Spitzer S, Smith R. Anti-fibrinogen IgG, Fibrinogen, and C1q complexes Circulating in a Hypofibrinogenemic Proband: Isolation, Stoichiometry, and Partial Characterization. Ann NY Acad Sci  936:  611-616, 2001.

Remijn JA, Lounes KC, Hogan KA, Lord ST, Galanakis DK, Sixma JJ, de Groot FG. Mutations on fibrinogen g 316-322 are associated with reduction in platelet adhesion under Flow Conditions. Ann NY Acad Sci 936: 444-448, 2001.

Invited Reviews and Commentaries

Galanakis, Dennis K. Dysfibrinogenemia: A current perspective. Clinics. Lab. Med. 4,395-418, 1984

Galanakis Dennis K. Fibrinogen Anomalies and Disease: a clinical update. Hem/Onc Clin North Amer 6: 1171, 1992.

Galanakis Dennis K. Inherited Dysfibrinogenemia: emerging dysfunctional structures. Sem Thromb Hemostas 19: 386-95, 1993.

Galanakis DK.  Disorders of Hemostasis.  BBANYS Quarterly 35: 3-7, 2001.

Galanakis DK. Progress on the afibrinogenemia-hypofibrinogenemia link. Blood, 2003; 101: 3342.

Galanakis DK.  Fibrin A knob caught in the act. Blood 2005; 106: 2933.

Galanakis DK. Another fibrin αC scene unmasked. Blood, 2005; 106: 3680.    

Galanakis DK. Plasma Cryoprecipitate: Molecular Origin and Clinical Relevance, BBANS Quarterly 2010; 44: (3): 26-29.

Galanakis DK. To Gel or Not to Gel. Blood, 2011; 117:4406-7.

Book Chapters
Galanakis Dennis K. Plasma Thrombin Times and Related Tests, Chapter in: Williams' Hematology, 5th edition, 1994, PP L91-L93.

Gorevic P, Galanakis DK, Finn AF.  Cryoglobulins Chapter in: Manual of Clinical Immunology, Am. Soc. of Microbiol., 5th, 6th, & 7th editions, 1997, 2001, 2015 respectively.   

Galanakis DK. Afibrinogenemia and Dysfibrinogenemia. Chapter 54.  in Marder et al, eds, text book Haemostasis and Thrombosis, basic principles and clinical practice. 6th Ed’n. Lippincott Williams & Wilkins, Philadelphia, New York, Baltimore, 2012.